| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.15 | 0.003 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.42 | 0.004 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.53 | 0.004 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.004 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.15 | 0.004 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | selumetinib:tretinoin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.099 | 0.005 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.093 | 0.005 |